Sarepta Therapeutics Inc (SRPT): Today's Featured Health Care Winner

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model

Sarepta Therapeutics ( SRPT) pushed the Health Care sector higher today making it today's featured health care winner. The sector as a whole closed the day down 0.9%. By the end of trading, Sarepta Therapeutics rose $0.55 (1.4%) to $39.46 on light volume. Throughout the day, 696,168 shares of Sarepta Therapeutics exchanged hands as compared to its average daily volume of 1,975,600 shares. The stock ranged in a price between $38.39-$39.72 after having opened the day at $38.54 as compared to the previous trading day's close of $38.91. Other companies within the Health Care sector that increased today were: Celsion Corporation ( CLSN), up 39.5%, Aegerion Pharmaceuticals ( AEGR), up 14.1%, IsoRay ( ISR), up 13.8% and Vermillion ( VRML), up 10.1%.
  • EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.

Sarepta Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery and development of RNA-based therapeutics for the treatment of rare and infectious diseases. Sarepta Therapeutics has a market cap of $1.2 billion and is part of the drugs industry. Shares are up 46.6% year to date as of the close of trading on Tuesday. Currently there are 10 analysts that rate Sarepta Therapeutics a buy, no analysts rate it a sell, and 2 rate it a hold.

TheStreet Ratings rates Sarepta Therapeutics as a sell. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income, disappointing return on equity, weak operating cash flow and feeble growth in its earnings per share.

On the negative front, Biota Pharmaceuticals ( BOTA), down 66.8%, TranS1 ( TSON), down 15.8%, Oculus Innovative ( OCLS), down 14.0% and ARCA biopharma ( ABIO), down 13.2% , were all laggards within the health care sector with Merck ( MRK) being today's health care sector laggard.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the health care sector could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health care sector could consider ProShares Ultra Short Health Care ( RXD).

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

null

More from Markets

Inside Carnival's Mind Blowing New Horizon Cruise Ship (Video)

Inside Carnival's Mind Blowing New Horizon Cruise Ship (Video)

Jim Cramer: The 10-Year Yield Could Go to 2.75%

Jim Cramer: The 10-Year Yield Could Go to 2.75%

Oil Slumps, Gas Spikes Ahead of Holiday Weekend; Assessing the Chipmakers--ICYMI

Oil Slumps, Gas Spikes Ahead of Holiday Weekend; Assessing the Chipmakers--ICYMI

Week Ahead: Wall Street Looks to Jobs Report as North Korea Meeting Less Certain

Week Ahead: Wall Street Looks to Jobs Report as North Korea Meeting Less Certain

Dow and S&P 500 Decline, Energy Shares Fall as U.S. Crude Oil Slides 4%

Dow and S&P 500 Decline, Energy Shares Fall as U.S. Crude Oil Slides 4%